Grant: CIHR Fellowship
McMaster University
$135,000.00
Evaluating the importance of muscle in treating metabolic dysfunction-associated steatohepatitis
EF 2023-24
Résumé
Metabolic dysfunction-associated steatohepatitis (MASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD), a disease that develops when fat builds up in the liver of a person who is not drinking alcohol. If that fat is accompanied by inflammation, it is called MASH. MASH is often associated with obesity and greatly increases a person's risk for diabetes, and even liver cancer if left untreated. Unfortunately, there are no approved drugs on the market for treating this condition, which is estimated to affect approximately 1 billion people worldwide. Therefore, it is important to better understand this disease so that we can develop drugs to treat MASH.
Although the exact cause of diabetes-induced liver disease is unknown, there is evidence that the imbalance between the energy expended by the body and the energy acquired through dietary intake plays a role in the development of MASH. Recently, research in our lab has demonstrated that a drug called recombinant human growth differentiating factor 15 (rhGDF15) is effective in treating MASH. GDF15 appears to improve MASH by increasing the expression of a protein called sarcolipin (Sln), a small protein found in muscle cells. Sln plays a pivotal role in regulating calcium ion (Ca2+) transport in skeletal muscles and influencing energy expenditure. Since increasing energy expenditure is an effective strategy to combat fatty liver diseases, we hypothesized that rhGDF15 improves MASH progression through targeting skeletal muscle Sln. If our hypothesis is correct, our research will identify a new approach for both the improvement of blood sugar levels and liver function in individuals with diabetes.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
492763
Name
Saed Christina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Evaluating the importance of muscle in treating metabolic dysfunction-associated steatohepatitis
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Diabetes; Fatty Liver; Metabolic Dysfunction-Associated Steatohepatitis (Mash); Obesity
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD), a disease that develops when fat builds up in the liver of a person who is not drinking alcohol. If that fat is accompanied by inflammation, it is called MASH. MASH is often associated with obesity and greatly increases a person's risk for diabetes, and even liver cancer if left untreated. Unfortunately, there are no approved drugs on the market for treating this condition, which is estimated to affect approximately 1 billion people worldwide. Therefore, it is important to better understand this disease so that we can develop drugs to treat MASH.
Although the exact cause of diabetes-induced liver disease is unknown, there is evidence that the imbalance between the energy expended by the body and the energy acquired through dietary intake plays a role in the development of MASH. Recently, research in our lab has demonstrated that a drug called recombinant human growth differentiating factor 15 (rhGDF15) is effective in treating MASH. GDF15 appears to improve MASH by increasing the expression of a protein called sarcolipin (Sln), a small protein found in muscle cells. Sln plays a pivotal role in regulating calcium ion (Ca2+) transport in skeletal muscles and influencing energy expenditure. Since increasing energy expenditure is an effective strategy to combat fatty liver diseases, we hypothesized that rhGDF15 improves MASH progression through targeting skeletal muscle Sln. If our hypothesis is correct, our research will identify a new approach for both the improvement of blood sugar levels and liver function in individuals with diabetes.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Saed, Christina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~